share_log

Ascendiant Capital Maintains Buy on PAVmed, Lowers Price Target to $21

Benzinga ·  Sep 10 05:31  · Ratings

Ascendiant Capital analyst Edward Woo maintains PAVmed (NASDAQ:PAVM) with a Buy and lowers the price target from $22 to $21.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment